Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Earnings Whisper Grade identifies where a stock is in the Earnings Expectation Life Cycle with the A+'s being in the Positive Earnings stage and, on average, gaining 7.42% from two days following the earnings release until the close just before its next earnings release - outperforming the overall stock market by 281%. Upjohn faced the expected headwind of generic competition for Lyrica in the Frank D’Amelio, Chief Financial Officer and Executive Vice President, Business Operations and Global Supply, stated, “We raised the midpoint of our 2020 financial guidance range for revenues and Adjusted diluted EPS“Despite the ongoing impact of COVID-19, 2020 is still expected to be a transformational year for Second-quarter 2020 revenues included an estimated net unfavorable impact of approximately Second-quarter 2020 diluted weighted-average shares outstanding used to calculate ReportedA comprehensive update of Pfizer’s development pipeline was published today and is now available at Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:(Note: If clicking on the above link does not open up a new web page, you may need to cut and paste the above URL into your browser's address bar. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. All rights reserved The operational variances are determined by multiplying or dividing, as appropriate, the current period In addition to the assumptions outlined in the 2020 Financial Guidance section of this press release, the 2020 financial guidance for (8) New Pfizer reflects contributions from the Biopharma business as it is presently being managed, which excludes contributions from Pfizer’s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in 2020 financial guidance for New Pfizer Adjusted IBT MarginFinancial guidance for New Pfizer operating cash flow includes a (10) Financial guidance for Upjohn reflects a full-year 2020 contribution from the Upjohn business as it is presently being managed, which includes contributions from Pfizer’s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in (11) Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) is defined as reported DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this earnings release and the related attachments is as of This earnings release and the related attachments contain forward-looking statements about our anticipated future operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, benefits anticipated from the reorganization of our commercial operations in 2019, plans for and prospects of our acquisitions and other business development activities, including our proposed transaction with Mylan N.V. (Mylan) to combine Upjohn and Mylan to create a new global pharmaceutical company and our transaction with GSK which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply, our efforts to respond to COVID-19, including our investigational vaccine candidate against SARS-CoV-2, our expectations regarding the impact of COVID-19 on our business, operations and financial results and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties. - the professionals' earnings expectation. Shares are up 0.9% since reporting last quarter. Pfizer (PFE) reported 2nd Quarter June 2020 earnings of $0.78 per share on revenue of $11.8 billion. Revenue fell 11.0% compared to … The Earnings Whisper number was $0.67 per share. )(1) The following acquisitions and other business development activity impacted financial results for the periods presented:(2) Revenues is defined as revenues in accordance with (3) Adjusted income and its components and Adjusted diluted EPS are defined as reported (4) Pfizer’s fiscal year-end for international subsidiaries is (5) References to operational variances in this press release pertain to period-over-period growth rates that exclude the impact of foreign exchange. In connection with the proposed combination of Past performance is not indicative of future results. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data.
EarningsWhispers is the only provider of real, professional whisper numbers for professional traders, with important fundamental, technical, and quantitative data and timely information, news, and advice. The consensus estimate was a loss of $0.63 per share on revenue of $31.68 billion for the quarter ending June 30, 2020. All rights reserved